


P0144

In vitro binding to human and NHP orthologs of candidate receptors identify novel systemically-delivered AAVs with enhanced CNS tropism

John Reece-Hoyes, Jackson Lee, Jie Tan, Estrella Lopez-Gordo, Caroline Curll, Fion Chan, Sri Siripurapu, Stephanie Malyszka, Kimberly Le, Allegra Fieldsend, Alex Needham, Haley Knight, Paul Freeman, Matt Bennett, Esther Aribilola, Ramin Kamran Sami, Shahrzad Parker, Jordan Shufro, Graham Lilley, Bryan Mastis, Roberto Calcedo, Matt Edwards, Sherry Cao, Charles F. Albright


Summary

- We have previously discovered BBB-penetrant AAV capsids that when delivered intravenously transduce >50% neurons in NHPs
- To identify additional capsids that lead to high CNS expression and broad CNS distribution, we screened AAV capsid libraries (7mer peptide insertions in AAV9 VR8) for binding to 10 putative human receptors that could facilitate BBB transcytosis, including Transferrin Receptor (TFRC), SLC3A2 (CD98), ALPL and CA4
- To address cross-species tropism early in the discovery pipeline we selected novel capsids that bound both human and NHP receptor orthologs
- This approach identified candidates with improved CNS tropism compared to AAV9





• Single cell RNA-seq of brain tissues was used to identify highly expressed (y-axis) and brain endothelial cell specific (xaxis) receptors in brain endothelial cells of mouse or vascular cells of human. Other features such as %CV across GTEx brain data were normalized to an endothelial specific gene (FLT1)

Method to isolate capsids using in vitro binding assay



Binding hits are reproducible and unique to a given receptor





R3

